Cervomed reports third quarter 2023 financial results and business highlights

Dosed first patient in phase 2b rewind-lb study evaluating neflamapimod in patients with dementia with lewy bodies (dlb) multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in dlb and probability of success in optimized rewind-lb study completed reverse merger; company now publicly traded on nasdaq ("crvo") cervomed has cash runway through the end of 2024, by which time the topline primary efficacy results from the phase 2b rewind-lb study are expected to be available boston , nov. 13, 2023 /prnewswire/ -- cervomed inc. (nasdaq: crvo), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced financial results for the third quarter ended september 30, 2023, and provided recent business highlights. "this has been an active and exciting quarter as we completed our merger and launch of cervomed, while also enrolling the first patient in our rewind-lb phase 2b study of neflamapimod for dementia with lewy bodies (dlb)," said john alam, md, chief executive officer of cervomed.
CRVO Ratings Summary
CRVO Quant Ranking